Identification of Prognostic Factors for Recurrence and Mortality in Patients With Acute Pulmonary Embolism


  • Weijia Zeng Department of Emergency, Fujian Provincial Hospital, Provincial College of Clinical Medicine, Fujian Medical University, Fuzhou, China
  • Bing Xu Department of Emergency, Fujian Provincial Hospital, Provincial College of Clinical Medicine, Fujian Medical University, Fuzhou, China
  • Xiaoping Wang Department of Emergency, Fujian Provincial Hospital, Provincial College of Clinical Medicine, Fujian Medical University, Fuzhou, China
  • Shirong Lin Department of Emergency, Fujian Provincial Hospital, Provincial College of Clinical Medicine, Fujian Medical University, Fuzhou, China
  • Qingming Lin
  • Zedong Hao Shanghai Synyi Medical Technology Co., Ltd, Shanghai, China
  • Feng Chen Department of Emergency, Fujian Provincial Hospital, Provincial College of Clinical Medicine, Fujian Medical University, Fuzhou, China
  • Jun Ke Department of Emergency, Fujian Provincial Hospital, Provincial College of Clinical Medicine, Fujian Medical University, Fuzhou, China



recurrence, mortality, acute pulmonary embolism, prognostic factors


Background: This study aimed to explore prognostic factors for 1-year recurrence and mortality in patients with acute pulmonary embolism (APE).

Methods: APE patients who attended the Emergency Department of Fujian Provincial Hospital from January 2016 to June 2020 were recruited. Univariate and multivariate logistic regression analyses were carried out to determine the prognostic factors for 1-year recurrence and mortality.

Results: A total of 458 APE patients were included, of whom 81 (17.69%) had recurrence, and 97 (21.18%) died. Multivariate logistic regression analyses revealed that smoke (OR: 1.949; 95% CI: 1.094–3.470; P = 0.023), abnormal platelet distribution width (OR: 3.013; 95% CI: 1.574–5.767; P = 0.001), and interrupted maintenance therapy (OR: 18.280; 95% CI: 9.777–34.179; P < 0.001) were significantly associated with an increased risk of 1-year recurrence in APE patients. Age ≥65 years (OR: 3.492; 95% CI: 1.876–6.500; P < 0.001), history of malignancy (OR: 7.190; 95% CI: 3.804–13.587; P < 0.001), history of long-term immobilization (OR: 6.244; 95% CI: 3.472–11.228; P < 0.001), mechanical ventilation (OR: 5.971; 95% CI: 3.154–11.304; P < 0.001), and interrupted maintenance therapy (OR: 2.414; 95% CI: 1.315–4.432; P = 0.004) were independent prognostic factors for 1-year mortality. The AUC of 1-year mortality and recurrence prediction models were 0.852 (95% CI: 0.805–0.898) and 0.868 (95%CI: 0.832–0.905).

Conclusion: In patients with APE, history of smoking, abnormal PDW, and interrupted maintenance therapy were significantly associated with the risk of 1-year recurrence, while age ≥65 years, history of malignancy, history of long-term immobilization, mechanical ventilation, and interrupted maintenance therapy were independent prognostic factors for 1-year mortality.


Caine GJ, Stonelake PS, Lip GY, Kehoe ST. 2002. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 4(6):465-73.

Casazza F, Becattini C, Bongarzoni A, Cuccia C, Roncon L, Favretto G, et al. 2012. Clinical features and short-term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thromb Res. 130(6):847-52.

Cheng YJ, Liu ZH, Yao FJ, Zeng WT, Zheng DD, Dong YG, et al. 2013. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 10(9): e1001515.

Chung T, Connor D, Joseph J, Emmett L, Mansberg R, Peters M, et al. 2007. Platelet activation in acute pulmonary embolism. J Thromb Haemost. 5(5):918-24.

Comfere TB, Sprung J, Case KA, Dye PT, Johnson JL, Hall BA, et al. 2007. Predictors of mortality following symptomatic pulmonary embolism in patients undergoing noncardiac surgery. Can J Anesth. 54(8):634-41.

Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, et al. 2016. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 133(9):859-71.

Ergan B, Ergün R, Çalışkan T, Aydın K, Tokur ME, Savran Y, et al. 2016. Mortality Related Risk Factors in High-Risk Pulmonary Embolism in the ICU. Can Respir J. 2432808.

Falanga A, Russo L, Milesi V, Vignoli A. 2017. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 118:79-83.

Faller N, Limacher A, Méan M, Righini M, Aschwanden M, Beer JH, et al. 2017. Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. Am J Med. 130(2):198-206.

Fernandes CJ, Luppino Assad AP, Alves-Jr JL, Jardim C, de Souza R. 2019. Pulmonary Embolism and Gas Exchange. Respiration. 98(3):253-62.

Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA. 2014. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 6:179-187.

Furlan A, Aghayev A, Chang CC, Patil A, Jeon KN, Park B, et al. 2012. Short-term mortality in acute pulmonary embolism: clot burden and signs of right heart dysfunction at CT pulmonary angiography. Radiology. 265(1):283-93.

Gambhir S, Grigorian A, Ashbaugh A, Spencer D, Ramakrishnan D, Schubl SD, et al. 2019. Early versus late pulmonary embolism in trauma patients: not all pulmonary embolisms are created similarly. J Surg Res. 239: 174-179.

Goldhaber SZ, Elliott CG. 2003. Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. Circulation. 108(23):2834-8.

Goldhaber SZ, Visani L, De Rosa M. 1999. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 353(9162):1386-9.

Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, Burgess S, et al. 2019. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 4(2): 163-173.

Günay E, Ulb_l1 SSn, Kaçar E, Halici B, Unlu E, Tünay K, et al. 2014. Can platelet indices predict obstruction level of pulmonary vascular bed in patients with acute pulmonary embolism? Clin Respir J. 8(1):33-40.

Gupta R, Fortman DD, Morgenstern DR, Cooper CJ. 2018. Short- and Long-term Mortality Risk After Acute Pulmonary Embolism. Curr Cardiol Rep. 20(12):135.

Haddad F, Doyle R, Murphy DJ, Hunt SA. 2008. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 117(13):1717-31.

Huang J, Chen Y, Cai Z, Chen P. 2015. Diagnostic value of platelet indexes for pulmonary embolism. Am J Emerg Med. 33(6):760-3.

Jiménez D, Lobo J, Barrios D, Prandoni P, Yusen R. 2016. Risk stratification of patients with acute symptomatic pulmonary embolism. Intern Emerg Med. 11(1):11-8.

Kapil S, Wilson JG. 2019. Mechanical Ventilation in Hypoxemic Respiratory Failure. Emerg Med Clin North Am. 37(3):431-44.

Kline JA, Miller DW. 2011. Risk stratification for acute pulmonary embolism. J Natl Compr Canc Netw. 9(7):800-10.

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2020. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 41(4):543-603.

Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, et al. 2008. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation. 117(13):1711-6.

Li XQ, Zhou C, Hu YH, Zhou HX, Shi CL, Tang YJ, et al. 2018. Comparison of risk factors and short-term and long-term prognosis of pulmonary embolism between the Tibetan and Han people. Zhonghua Yi Xue Za Zhi. 98(40):3249-3252.

Mabrouk B, Anis C, Hassen D, Leila A, Daoud S, Hichem K, et al. 2014. Pulmonary thromboembolism: incidence, physiopathology, diagnosis and treatment. Tunis Med. 92(7):435-47.

Meneveau N, Ming L, Mersin N, Schiele F, Caulfield F, Bernard Y, et al. 2003. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J. 24(15):1447-54.

Nauffal D, Ballester M, Reyes RL, Jiménez D, Otero R, Quintavalla R, et al. 2012. Influence of recent immobilization and recent surgery on mortality in patients with pulmonary embolism. J Thromb Haemost. 10(9):1752-60.

Ng AC, Chung T, Yong AS, Wong HS, Chow V, Celermajer DS, et al. 2011. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes. 4(1):122-8.

Nielsen VG, Hafner DT, Steinbrenner EB. 2013. Tobacco smoke-induced hypercoagulation in human plasma: role of carbon monoxide. Blood Coagul Fibrinolysis. 24(4): 405-10.

Park Y, Schoene N, Harris W. 2002. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 13(5-6):301-6.

Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O'Neil BJ, et al. 2011. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol. 57(6):700-6.

Ruiz-Fernández D, Monsalve Torra A, Soriano-Payá A, Marín-Alonso O, Triana Palencia E. 2016. Aid decision algorithms to estimate the risk in congenital heart surgery. Comput Methods Programs Biomed. 126:118-27.

Salahuddin S, Prabhakaran D, Roy A. 2012. Pathophysiological mechanisms of tobacco- related CVD. Glob Heart. 7(2): 113-120.

Søgaard KK, Schmidt M, Pedersen L, Horváth-Puhó E, Sørensen HT. 2014. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 130(10):829-36.

The urokinase pulmonary embolism trial. 1973. A national cooperative study. Circulation. 47(2 Suppl):II1-108.

Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. 2010. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 14(1):28-32.

van der Bijl N, Klok FA, Huisman MV, van Rooden JK, Mertens BJA, de Roos A, et al. 2011. Measurement of right and left ventricular function by ECG-synchronized CT scanning in patients with acute pulmonary embolism: usefulness for predicting short-term outcome. Chest. 140(4):1008-15.

Varol E, Icli A, Uysal BA, Ozaydin M. 2011. Platelet indices in patients with acute pulmonary embolism. Scand J Clin Lab Invest. 71(2):163-7.

Wiesholzer M, Kitzwögerer M, Harm F, Barbieri G, Hauser AC, Pribasnig A, et al. 1999. Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis. 33(4):702-8.

Wong PC, Crain EJ, Watson CA, Xin B. 2009. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 7:1313-1320.

Yildirimturk O, Nurkalem Z, Özcan K, Altay S, Satilmis S, Bozbeyoğlu E. 2012. Predictors of in-hospital and long term mortality in patients with acute pulmonary embolism. J Am Coll Cardiol. 59.

Zhou FL, Wang LH, Dai CQ, Shentu GJ, Xu GH. 2021. Risk Factors and Outcomes for Preoperative Asymptomatic Pulmonary Embolism in Patients Aged 60 Years and Over with Hip Fracture. Orthop Surg. 13(3):958-965.



How to Cite

Zeng, W. ., Xu, B. ., Wang, X. ., Lin, S. ., Lin, Q. ., Hao, Z. ., Chen, F., & Ke, J. . (2022). Identification of Prognostic Factors for Recurrence and Mortality in Patients With Acute Pulmonary Embolism. The Heart Surgery Forum, 25(6), E812-E821.